We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

25 hedge funds and large institutions have $46.5M invested in Xenon Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

3% more capital invested

Capital invested by funds: $45.2M → $46.5M (+$1.25M)

0% more funds holding

Funds holding: 25 → 25 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Holders
25
Holders Change
–
Holders Change %
0%
% of All Funds
0.66%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
3
Increased
7
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
OM
Opaleye Management
Massachusetts
+$1.27M
2
BI
BVF Inc
California
+$771K
3
DCM
DAFNA Capital Management
California
+$623K
4
Renaissance Technologies
Renaissance Technologies
New York
+$159K
5
UBS Group
UBS Group
Switzerland
+$22.5K

Top Sellers

1
GCP
GSA Capital Partners
United Kingdom
-$241K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$86K
3
IPC
Invesco Private Capital
New York
-$70.9K
4
Deutsche Bank
Deutsche Bank
Germany
-$36.3K
5
Bank of America
Bank of America
North Carolina
-$18K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$9.05M +$771K +90,000 +9%
Capital World Investors
2
Capital World Investors
California
$8.28M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$7.32M – – –
Royal Bank of Canada
4
Royal Bank of Canada
Ontario, Canada
$3.77M – – –
VAM
5
Visium Asset Management
New York
$3.54M – – –
IPC
6
Invesco Private Capital
New York
$3.51M -$70.9K -8,271 -2%
Point72 Asset Management
7
Point72 Asset Management
Connecticut
$2.55M – – –
OM
8
Opaleye Management
Massachusetts
$2.41M +$1.27M +148,700 +98%
PA
9
Perceptive Advisors
New York
$1.66M – – –
NHAS
10
Novo Holdings A/S
Denmark
$1.03M – – –
DCM
11
DAFNA Capital Management
California
$786K +$623K +72,730 +291%
JC
12
JBF Capital
Colorado
$552K – – –
State of New Jersey Common Pension Fund D
13
State of New Jersey Common Pension Fund D
New Jersey
$523K – – –
WMSA
14
Weiss Multi-Strategy Advisers
New York
$362K +$22.3K +2,600 +6%
Renaissance Technologies
15
Renaissance Technologies
New York
$314K +$159K +18,605 +91%
GCP
16
GSA Capital Partners
United Kingdom
$304K -$241K -28,150 -43%
LWIC
17
Leith Wheeler Investment Counsel
British Columbia, Canada
$178K +$138K +16,075 New
NSEDCP
18
NJ State Employees Deferred Compensation Plan
New Jersey
$161K – – –
Deutsche Bank
19
Deutsche Bank
Germany
$61K -$36.3K -4,238 -36%
Bank of Montreal
20
Bank of Montreal
Ontario, Canada
$57K -$7.71K -900 -11%
Wells Fargo
21
Wells Fargo
California
$37K +$19.7K +2,300 +102%
UBS Group
22
UBS Group
Switzerland
$21K +$22.5K +2,629 New
TRCT
23
Tower Research Capital (TRC)
New York
$10K +$2.86K +334 +36%
Morgan Stanley
24
Morgan Stanley
New York
$7K +$7.86K +917 New
Citigroup
25
Citigroup
New York
$6K – – –
1
2

XENE Hedge Fund Activity: Q4 2015 in Review

25 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2015, worth a combined $46.5M — up 2.8% from $45.2M a quarter earlier.

Fund positioning in XENE was balanced in Q4 2015: 3 funds opened new positions, 3 closed out, 7 added to existing stakes and 4 trimmed.

The largest buyer was Opaleye Management, adding an estimated $1.27M. The largest seller was GSA Capital Partners, cutting an estimated $241K.

  • 25 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2015, unchanged from Q3 2015.
  • Funds reported $46.5M of Xenon Pharmaceuticals stock for Q4 2015, up 2.8% quarter-over-quarter.
  • 3 funds opened new Xenon Pharmaceuticals positions in Q4 2015 and 3 closed out, a net change of 0 holders.
  • The largest Xenon Pharmaceuticals buyer in Q4 2015 was Opaleye Management, an estimated $1.27M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2015 was GSA Capital Partners, an estimated $241K sold.

Based on aggregated 13F filings for Q4 2015.